At present, the one FDA accredited biomarker for ICI melanoma remedy is the tumor mutation burden assay, however the mechanisms linking it to ICI stay unclear. Nonetheless, new analysis now supplies proof of novel, dependable biomarkers that predict remedy response utilizing superior pc know-how.